Business
Nutra Pharma Announces Additional Orphan Drug Application for RPI-78M for the Treatment of Myasthenia Gravis
Nutra Pharma Announces Additional Orphan Drug Application for RPI-78M for the Treatment of Myasthenia Gravis.
About this update from Nutra Pharma Corp.
[{"type":"text","content":"\n \n \n Nutra Pharma Announces Additional Orphan Drug Application for RPI-78M for the Treatment of Myasthenia Gravis\n \n \nNutra Pharma Announces Additional Orphan Drug Application for RPI-78M for the Treatment of Myasthenia Gravis\n \n CORAL SPRINGS, FL--(Marketwired - Dec 9, 2015) - Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away in the over-the-counter (OTC) pain management market, as well as developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have applied for an Orphan Drug designation from the US-FDA for the Company's RPI-78M drug candidate for the treatment of Myasthenia Gravis (MG). On September 8, 2015, the Company announced that they had been granted an Orphan Designation for the treatment of Pediatric Multiple Sclerosis. The designation is designed to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.\n \"We have been clear over the last year that we would be moving our drug platforms forward,\" stated Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. \"This includes our work in Pediatric Multiple Sclerosis as well as additional potential Orphan Designations for our therapeutic pipeline. We expect to receive the orphan designation for MG. In the meantime, we will continue to work with our FDA consultants to prepare for an Investigative New Drug Application as we develop the clinical trial protocols for Pediatric MS.\"\n Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal (voluntary) muscles of the body. The name myasthenia gravis, which is Latin and Greek in origin, literally means \"grave muscle weakness.\" The hallmark of myasthenia gravis is muscle weakness that increases during periods of activity and improves after periods of rest. Certain muscles such as those that control eye and eyelid movement, facial expression, chewing, talking, and swallowing are often, but not always, involved in the disorder. The muscles that control breathing and neck and limb movements may also be affected. RPI-78M is believed to be effective in the treatment of MG through the modulation of the immune system, preventing autoimmune effe...